Tags : Lilly

PharmaShots Weekly Snapshots (August 23 – 27, 2021)

Tuba Khan August 27, 2021

Ascendis’ Skytrofa (lonapegsomatropin-tcgd) Receives the US FDA’s Approval for Pediatric Growth Hormone Deficiency Published: Aug 27, 2021 | Tags: Ascendis, Skytrofa, lonapegsomatropin-tcgd, US, FDA, Approval, Pediatric Growth Hormone Deficiency Amgen Presents Results of Repatha (evolocumab) in P-III HUYGENS Study for the Treatment of Acute Coronary Syndrome at ESC 2021 Published: Aug 27, 2021 | Tags: […]Read More

Biotech

Lilly Signs a License Agreement with Lycia to Develop Novel

Tuba Khan August 26, 2021

Shots: Lycia to receive $35M up front and is also eligible to receive an additional ~$1.6B upon the achievement of milestones along with royalties on sales of the product emerges from the collaboration Lilly will be responsible for the pre/clinical development of the product and also gets an exclusive global license to commercialize the product […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshots (August 16 – 20, 2021)

Tuba Khan August 20, 2021

Janssen Presents Results of Rybrevant (amivantamab-vmjw) in P-I CHRYSALIS Study for Advanced NSCLC with METex14 Mutations at WCLC Published: Aug 20, 2021 | Tags: Astellas, FibroGen, Evrenzo, Roxadustat, EC, Approval, Symptomatic Anemia, Chronic Kidney Disease Astellas and FibroGen’s Evrenzo (roxadustat) Receive EC’s Approval for Symptomatic Anemia Associated with Chronic Kidney Disease Published: Aug 20, 2021 […]Read More

Clinical Trials

Lilly Reports Results of Lebrikizumab in P-III ADvocate 1 and

Tuba Khan August 16, 2021

Shots: The ongoing P-III ADvocate 1 & 2 studies evaluate lebrikizumab as monothx. vs PBO in adult & adolescent patients aged 12 to less than 18 yrs. with mod. to sev. AD for 52wks. The 1EPs & 2EPs of study i.e >75% change from baseline in EASI score @16wks., improvement in skin clearance & itch […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshots (August 02 – 06, 2021)

Tuba Khan August 6, 2021

Medtronic to Acquire Intersect ENT for ~$1.1B Published: Aug 6, 2021 | Tags: Medtronic, Intersect ENT, ~$1.1B Kite Signs a License Agreement with Appia to Develop Allogeneic Cell Therapies for the Treatment of Cancer Published: Aug 6, 2021 | Tags: Kite, Appia, Allogeneic Cell Therapies, Cancer Polpharma & Bioeq Report BLA Submission to the US […]Read More

Clinical Trials

Lilly and Incyte Report Results of Baricitinib in P-III COV-BARRIER

Tuba Khan August 3, 2021

Shots: The P-III COV-BARRIER substudy evaluates baricitinib + SoC vs PBO + SoC in 101 adult patients with COVID-19 who are on mechanical ventilation or extracorporeal membrane oxygenation (ECMO) The results showed reduction in mortality (46% & 44%) @ Day 28 & 60. The findings are consistent with the reduction in mortality in the overall […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshots (July 26 – 30, 2021)

Tuba Khan July 30, 2021

Roche Publishes the Results of Evrysdi (risdiplam) in FIREFISH Study to Treat of Type 1 SMA at NEJM Published: July 30, 2021 | Tags: Roche, Evrysdi, risdiplam, FIREFISH Study, Type 1 SMA, NEJM BeiGene Reports Results of Brukinsa (zanubrutinib) in P-III SEQUOIA Trial for the Treatment of Chronic Lymphocytic Leukemia Published: July 30, 2021 | […]Read More

Biotech

Lilly Collaborates with Kumquat to Develop Novel Small Molecules that

Tuba Khan July 30, 2021

Shots: Kumquat to receive an ~ $70M in upfront and an equity investment in addition to ~$2B in milestone based on the achievement of definite milestones along with royalties on sales of commercialized products resulting from the collaboration Following the agreement, Lilly gets the option to co-commercialize in China while Kumquat has the option to […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshots (July 05 – 09, 2021)

Tuba Khan July 9, 2021

Lysogene Receives the US FDA’s Fast Track Designation for LYS-GM101 Gene Therapy to Treat GM1 Gangliosidosis Published: July 9, 2021 | Tags: Lysogene, US, FDA, Fast Track Designation, LYS-GM101 Gene Therapy, GM1 Gangliosidosis Jazz’s Vyxeos (daunorubicin and cytarabine liposome) for Injection Receives Health Canada Approval for the Treatment of High-risk Acute Myeloid Leukemia Published: July […]Read More

Insights+

PharmaShots’ Key Highlights of Second Quarter 2021

Tuba Khan July 1, 2021

The second quarter of 2021 witnesses major acquisitions, approvals, and clinical data. There are major alliances in this quarter which include Merck signed ~$1.2B supply agreement with US Government for Molnupiravir to treat COVID-19 The big acquisition took place during the quarter including Microsoft acquired Nuance for ~$19.7B, MorphoSys acquired Constellation for ~$1.7B Our team […]Read More

Takeda Enters into an Exclusive License Agreement with Mirum to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan

Amgen Collaborates with Verastem to Evaluate VS-6766 + Lumakras (Sotorasib) in P-I/II Trial for KRAS G12C-Mutant Non-Small Cell Lung Cancer

Immunic Sign a License Agreement with University Medical Center Goettingen for IMU-838 & N4-Hydroxycytidine to Treat Viral Infections

AbCellera Enters into a License Agreement with Everest to Discover Antibody Therapies

Samsung Bioepis and Biogen’s Byooviz (biosimilar, ranibizumab) Receives the US FDA’s Approval for the Treatment of Retinal Vascular Disorders

Samsung Bioepis Reports Results of Post-Hoc Analysis from P-III Study of Byooviz (biosimilar, ranibizumab) for the Treatment of nAMD

Immunic Sign a License Agreement with University Medical Center Goettingen for IMU-838 & N4-Hydroxycytidine to Treat Viral Infections

Gilead Reports Results of Veklury (remdesivir) in P-III Trial for the Treatment of COVID-19

Incyte’s Jakafi (ruxolitinib) Receives the US FDA’s Approval for the Treatment of Chronic Graft-Versus-Host Disease

Innovent Reports NMPA’s Acceptance of sNDA for Sintilimab as 1L Treatment for Esophageal Squamous Cell Carcinoma

Gilead Reports Results of Veklury (remdesivir) in P-III Trial for the Treatment of COVID-19

Vigeo Reports Completion of VT1021 in P-I/II Study for the Treatment of Recurrent Glioblastoma and Pancreatic Cancer

Tags : Lilly

PharmaShots Weekly Snapshots (August 23 – 27, 2021)

Lilly Signs a License Agreement with Lycia to Develop Novel

PharmaShots Weekly Snapshots (August 16 – 20, 2021)

Lilly Reports Results of Lebrikizumab in P-III ADvocate 1 and

PharmaShots Weekly Snapshots (August 02 – 06, 2021)

Lilly and Incyte Report Results of Baricitinib in P-III COV-BARRIER

PharmaShots Weekly Snapshots (July 26 – 30, 2021)

Lilly Collaborates with Kumquat to Develop Novel Small Molecules that

PharmaShots Weekly Snapshots (July 05 – 09, 2021)

PharmaShots’ Key Highlights of Second Quarter 2021

Latest Posts

ViewPoints Article: 5 Technologies That Redefines Human Medicine and Therapeutics

Immunic Sign a License Agreement with University Medical Center Goettingen for IMU-838 & N4-Hydroxycytidine to Treat Viral Infections

Gilead Reports Results of Veklury (remdesivir) in P-III Trial for the Treatment of COVID-19

Incyte’s Jakafi (ruxolitinib) Receives the US FDA’s Approval for the Treatment of Chronic Graft-Versus-Host Disease

Tags : Lilly

Latest Posts

Categories

Related Topics